Connect with us


Campaigner responds to Irish doctors proposal to shun MCAP

Irish doctors have expressed concerns over the scheme, designed to improve access to medical cannabis



MCAP programme: neurologists holds a yellow bottle of oil with a dropper against a lab coat
Nine neurologists have written to Ireland's Health Minister expressing concern over the products

High profile campaigner Vera Twomey has responded to neurologists who expressed concern over products likely to be offered through the Medical Cannabis Access Programme.

Doctors treating patients with epilepsy appear to be planning to shun the Irish Government’s Medical Cannabis Access Programme (MCAP).

Several neurologists and patient organisations have written to Minister for Health Stephen Donnelly with concerns about the products being made available under the scheme, citing fears they are “inappropriate” and “potentially harmful”.

Widespread concern

As reported by the Irish Times, the letter states:

“Not only is there a lack of evidence to support the use of THC in epilepsy, but there are significant concerns regarding its psychiatric and cognitive effects, particularly when used in children.”

All four products accepted for the programme contain THC, with those behind the letter concerned that the risks associated with THC compounds are under-appreciated.

The neurologists say that because of widespread concern, the programme now runs the risk of not being used.

The letter continued: “Because there is widespread concern about the programme among neurologists in Ireland (because inappropriate and potentially harmful products will be available through the programme), the programme runs the risk of not being utilised.”

However, despite being introduced in 2019, the MCAP still not operational. The pilot programme is set to run for five years although it is unclear if this will be extended as a result of Covid-19 disruption.

Read more: Ireland to fund patient’s medical cannabis upfront

Supply issues

There are currently no cannabis-based products available under the programme or any patients registered with the scheme.

One product has been approved for potential patients but doctors have expressed concern that the THC level is too high for a starting cannabinoid treatment for epilepsy patients. Another product has been deemed suitable by doctors, but as it is UK-manufactured there would need to be a change in legislation before it was made accessible in Ireland.

The HSE has reported that one supplier is now no longer interested in the Irish market. The products were due to be available in October or November this year but it is thought this could be pushed back due to the country of manufacture being changed.

Read more: Calls for reform to Ireland’s cannabis laws as hundreds prepare to protest

Patient response

Campaigner and mother Vera Twomey has spoken out about her concerns regarding the letter.

In a social media post, referring to how her daughter condition was improved through full extract cannabis oil, she said: “Twenty to 30 or 40 seizures a day or more eliminated by CBD and THC. The threat of further brain damage was removed almost completely. The thought that a negative campaign towards such a remarkable medication as CBD and THC is in full flow within our Republic of Ireland is a complete and utter disgusting travesty.

“The thought that families will be scared off exploring the option of THC medication by such extraordinary and unjustified measures such as refusing to acknowledge the programme set up to prescribe CBD and THC medication is one of the most destructive steps I have seen in seven years and smacks of desperation to stop access to cannabis medication.”

She added: “It is clear that the public is aware and informed of the benefits of medical cannabis because if they were not consultants would not be trying to create more barriers to access. I applaud the consultants sensible enough to prescribe this life-saving medication. I do not want to consider in much detail the real reasons why other consultants do not.”


There are plans to start enrolling patients on a cannabis medical use register once documentation is finalised. The department is currently working on this alongside specialists.

Twomey’s daughter Ava, is one of approximately 63 patients accessing medical cannabis in Ireland using the ministerial licence.

Until the start of the pandemic, patients had to travel to the Netherlands to import the drug back to Ireland. It is now sent directly as a result of disruption to travel. Earlier this year it was announced that cannabis medication would no longer need to be reimbursed from the HSE but would be funded upfront.

There are currently three conditions that qualify for medical cannabis in Ireland: severe epilepsy, spasticity associated with multiple sclerosis and nausea associated with chemotherapy. But patient organisations and activists say this does not go far enough and that there needs to be the inclusion of chronic pain patients.

Cannabis Health has approached HSE and the doctors involved for comment.


Fair Trials and Last Prisoner Project seek to launch global cannabis justice project

Fair Trials’ Global CEO Norman L. Reimer to discuss the project at Cannabis Europa Conference in London on June 29.



fair trials cannabis justice

A new initiative from Fair Trials and the Last Prisoner Project aims to redress the harm caused by cannabis prohibition and to secure relief for those in prison for cannabis-related convictions.

The criminal justice reform NGO, Fair Trials hopes that the industry will support its work in countries across the globe where cannabis laws are being liberalised. Through collaboration with local partners in appropriate jurisdictions, the Fair Trials project will identify people in need of legal assistance, and recruit, train and match volunteer lawyers to take on their cases.

Fair Trials has enlisted the help of the Last Prisoner Project, a coalition of cannabis industry leaders, executives and artists dedicated to bringing restorative justice to the cannabis sector.

More and more jurisdictions are allowing adults to use and distribute medical and recreational cannabis. But after decades of prohibition, countless people remain behind bars or continue to suffer the collateral consequences of a cannabis conviction.

US research programme studies cannabinoids in ovarian cancer

“The injustice of cannabis prohibition has resulted in millions of people worldwide serving time in prison or being saddled with a cannabis conviction, which brings with it a lifetime of harmful consequences, ranging from education and employment opportunities to immigration status and parental rights,” said Fair Trials Global CEO, Norman L Reimer.

“Of course, these harmful effects of prohibition not only impact the individuals charged, but also their families and communities. And those effects have been borne disproportionately by minorities, communities of colour, and the socio-economically disadvantaged. Legalising cannabis alone does not equal justice. Together, we must address the ongoing harms of past prohibition and leave no cannabis prisoner behind.”

The project will be modelled on the US Cannabis Justice Initiative, a collaborative effort between the cannabis industry and volunteer lawyers in the United States. When Norman Reimer was the Executive Director of the National Association of Criminal Defense Lawyers (NACDL), he partnered with the Last Prisoner Project to establish the initiative.

“Key to the success of the initiative has been generous donations from legal cannabis companies and consumers nationwide,” said Last Prisoner Project Co-Founder Steve DeAngelo. “Fair Trials, with its global reach as the world’s criminal justice watchdog, is uniquely positioned to build and house the infrastructure that’s going to be needed.”

Tomorrow (29 June), Norman Reimer will address the Cannabis Europa Conference discussing the project. Mr Reimer will be part of a panel entitled ‘Leave No Cannabis Prisoner Behind,’ and will be joined on that panel by Mary Bailey, Managing Director at the Last Prisoner Project; Dr. Laura Garius, Policy Lead at Release; and Denzel Uba, an individual impacted by criminal cannabis prohibition.

Continue Reading


TOWIE star Amy Childs launches CBD range in honour of Jorja Foundation

The product range sees a portion of the proceeds going to the Jorja Foundation.



Amy Childs at the launch of her new CBD range, Jorja Botanicals

TOWIE star Amy Childs launched her new CBD range this week, with a star-studded event that shone a spotlight on the story of six-year-old Jorja Emerson.

Amy Childs was joined by former Love Islanders, Amy Hart and Cara Delahoyde-Massey, alongside her  co-stars, Frankie Essex, Tom Skinner, Carina Lepore, Saffron Lempriere and Mark Ferris, for a heart-warming event celebrating the launch of her new CBD Infused beauty range, Jorja Botanicals.

The signature collection sees a portion of the proceeds going to the Jorja Foundation, which was set up in honour of six-year-old medical cannabis patient, Jorja Emerson.

The event saw The Only Way Is Essex star Frankie Essex, break down in tears as she heard Jorja’s story. Frankie, who gave birth to twins four weeks ago, wiped her eyes when Robin Emerson, Jorja’s father, showed videos of the life-threatening seizures his daughter was suffering before they discovered medical cannabis

Love Island star, Amy Hart has since taken to Instagram to spread the word about the latest political campaign that sees Childs and Emerson petitioning to make medical cannabis more widely available on the NHS

The Jorja Botanicals range was inspired by Jorja, who was diagnosed with a rare chromosome abnormality called 1q43q44 deletion, which has a side effect of life-threatening seizures. Her illness resulted in her being admitted to intensive care on two separate occasions, where Robin was told that she may not make it.

jorja botanicals

TOWIE stars joined Amy Childs for the launch of her new CBD range

To save his daughter’s life, Emerson knew that he had to dig deep and find a treatment that would not only help Jorja but ultimately go on to help others.

At the time it was still illegal to prescribe cannabis in the UK. Emerson joined the campaign to see medical cannabis legalised in the UK in November 2018, and Jorja’s was among the first children to be legally prescribed medicinal cannabis.

In 2021 he went on to create the Jorja Foundation – a charity set up to help other families and children going through the same battles that Robin had to face.

The Jorja Foundation’s core principles are to fund special needs equipment that is not funded through the health system, fund family counselling, private appointments and tests when a second opinion is needed, as well s cannabis-based treatment for children in the UK and to continue to campaign and educate for wider NHS access in the UK for cannabis-based medications.  

Childs commented: “When I saw Robin & Jorja’s story on social media it broke my heart.

As a mum, I couldn’t imagine the pain of being told to take my child home to say goodbye to them. I love that Robin has fought for Jorja & is now helping other families with the Jorja Foundation. 

“I’m so happy that I can help the foundation by being the Creative Director of Jorja Botanicals. We have created some beautiful products for the whole family to enjoy. We will be donating a percentage of the proceeds to the foundation so that we can help as many families as possible. ”

 Emerson added: “ This is the fruition of a lot of hard work over many months and I am extremely proud to launch what is the first family brand in this category. In the coming weeks, we will also be launching a ‘parent’ focused cosmetic range in partnership with our creative director Amy Childs and our premium line of tincture oils.”


Home » News » Campaigner responds to Irish doctors proposal to shun MCAP

Continue Reading


South Africa launches first trial of cannabis for chronic pain

The study will test whether cannabis can replace opioids in the management of chronic pain.



south africa cannabis trial

South Africa’s first cannabis trial has launched after initial results “show promise” for the treatment as a replacement for opioids.

The Pharma Ethics Observational Study is led by Biodata, a subsidiary of Labat Africa, and will test whether cannabis can replace opioids in the management of chronic pain.

The study will involve 1,000 participants who have been taking opioids for pain management for at least three months and are prepared to switch to cannabis as an alternative.

Biodata is the brainchild of Dr Shiksha Gallow, a cannabis clinician and the principal investigator in the trial which took over 18 months to get official clearance.

US research programme studies cannabinoids in ovarian cancer

Dr Gallow said the trial is set to be ground-breaking as South Africa’s first real-world study of medical cannabis. Researchers predict that it will provide much-needed insight into the link between cannabis genetics and patient outcomes.

Dr Gallow told Cannabiz Africa: “We are currently recruiting patients, and data-capturing all the questionnaires and feedback from the patients for the live Study. It has been fairly slow. However, more options have been introduced, as suggested by the patients in the pilot study.

“The pilot results of the study were very promising, as it showed 98 per cent of the patients have some sort of pain relief from the cannabis.

“We were able to wean these patients off their opioid treatment. In the pilot group of patients below the age of 55, it was shown this group preferred to smoke cannabis and patients older than 55 years preferred oil. The patients who smoked the cannabis had relief almost immediately, while the oil took some time to alleviate their pain.”

“Once we reach the sample size required and all of the relevant data has been collated, the results of the study will be published. We have currently renewed this study for another year, due to the initial slow uptake of research participants.”

Patients can apply to be research participants through the Biodata website.

Labat is expanding its footprint over the next few months with the introduction of CannAfrica kiosks in major shopping malls.

The company believes these will be the “ideal locations for physical sign-up points for the study”.

Labat said the kiosks will also serve as Biodata dispensaries and is engaging with a number of vape stores to do the same, although these would have to be subject to South African Health Products Regulatory Authority’s pharma-ethics requirements.

Home » News » Campaigner responds to Irish doctors proposal to shun MCAP

Continue Reading